정책연구보고서

• 목록

 

 

Ⅰ. 배경 및 목적 ······································································································ 1
 

Ⅱ. IARC 조직 및 역할 ··························································································· 2
 

1. 연혁 ······················································································································ 2
 

2. 조직 ······················································································································ 2
 

3. IARC 역할 ··········································································································· 3
 

Ⅲ. IARC의 발암물질 평가 프로세스 (세부사항 붙임1참조) ·························· 4
 

1. IARC 발암성 물질 선정 절차 ··········································································· 4
 

2. IARC Monographs의 구성 및 발암성 평가 지침 ········································· 5
 

3. IARC Monographs의 발암성 등급 분류 및 설명 ········································· 8
 

Ⅳ. 발암물질 평가회의(기초 자료) ····································································· 10
 

1. 평가회의 참가자의 구성 ·················································································· 10
 

2. 평가회의 참가자의 역할 ·················································································· 10
 

3. 평가 업무 절차 ································································································· 10
 

4. 2014년 9월 평가회의 실무 작업반(Working group)의 구성 ······················ 11
 

5. 실무 작업반이 검토하는 자료의 수준 ··························································· 11
 

6. 각 실무 작업반이 작성하는 평가서 (monograph)의 내용 ························· 11
 

Ⅴ. CNT 발암성 관련 자료 ··················································································· 13
 

1. CNT 발암물질 평가대상 설정배경 ································································· 13
 

2. CNT의 발암성 평가에 영향을 미치는 출판물 ·············································· 14
 

3. CNT의 발암성 관련 논문 ················································································ 14
 

4. CNT의 사람에 대한 영향 논문 ······································································ 16
 

5. CNT의 단기 흡입독성시험 ·············································································· 17
 

6. CNT의 독성기전 ······························································································· 18

 

Ⅵ. IARC 발암성 평가 기준 ·················································································· 19

 

Ⅶ. 탄소나노튜브(CNT)의 발암성 물질 평가 결과 ············································ 20
 

Ⅷ. 탄소나노튜브(CNT) 발암성 평가의 문제점 및 한계점 ······························· 21
 

1. 탄소나노튜브(CNT)가 모두 동일한가? ··························································· 21
 

2. 탄소나노튜브(CNT)와 석면이 유사한가? ······················································· 21
 

3. 동물실험이나 in vitro 에서 얻어진 결과가 실제 인간의 노출에 근거하고 있는가? ····················· 21
 

4. 동물실험에서의 발암과 in vivo, in vitro 발견되는 독성기전에 실제 사람에게 나타나는가? ····· 21
 

Ⅸ. CNT 발암물질 분류 이후의 예상되는 영향 ··············································· 23
 

1. 유해등급에 따른 발암물질 관리 방안 ··························································· 23
 

2. 규제적 조치 ······································································································· 23
 

3. CNT의 발암의심물질 지정이 다른 Group 2B 물질과의 차이점 ··············· 24
 

Ⅹ. 향후 전망 ········································································································· 25
 

Ⅺ. 대응방향 ··········································································································· 26
 

1. 정부의 대응방향 ································································································ 26
 

2. 기업의 대응방향 ································································································ 27
 

참고문헌 ·················································································································· 29
 

[부록] 발암물질 분류 평가 지침서(Preamble) ················································ 30